Steven Chen, MD
Ophthalmology · Glendale, AZNPI 1043201999
Payments from drug & device makers
Across 79 payments — averaging $32.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$913
- Trisalus Life Sciences, Inc.$284
- Alcon$240
- Glaukos Corporation$229
- Eyevance Pharmaceuticals LLC$171
- Imperative Care, Inc$122
- plus $607 from 12 others
What the payments were for
- Food & beverage$2,565100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 51 | $913 |
| Trisalus Life Sciences, Inc. | 2 | $284 |
| Alcon | 3 | $240 |
| Glaukos Corporation | 2 | $229 |
| Eyevance Pharmaceuticals LLC | 1 | $171 |
| Imperative Care, Inc | 2 | $122 |
| Ivantis, Inc | 1 | $109 |
| Dompe US, Inc. | 1 | $95 |
| Sun Pharmaceutical Industries Inc. | 3 | $77 |
| Merz North America, Inc. | 2 | $74 |
| Penumbra, Inc. | 2 | $73 |
| EKOS Corporation | 2 | $38 |
| Boston Scientific | 2 | $33 |
| Kedrion Biopharma, Inc. | 1 | $33 |
| Revance Therapeutics, Inc. | 1 | $24 |
| Sirtex Medical Inc | 1 | $19 |
| Bard Peripheral Vascular, Inc. | 1 | $17 |
| AbbVie | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRINAV INFUSION SYSTEM$284
- Flarex$171
- iDoseTR$155
- TEPEZZA$125
- Hydrus$109
How this compares
$2,565 in reported general payments places this provider in the 60th percentile of 310 ophthalmology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErythromycinErythromycin Base | 317 | $3,077 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 105 | $1,056 |
| Diazepam | 24 | $39 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Glendale
- George ReissGlendale$1.3M
- Shamil PatelGlendale$457K
- Sara GhobraielGlendale$345K
- Wendy HuangGlendale$73K
- Anne FloydGlendale$11K
- Mark BarakatScottsdale$2.9M
- Michael DepenbuschChandler$2.3M
- Ramin SchadluPhoenix$1.8M
- Gerald WalmanSun City$1.7M
- John CasonPhoenix$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.